The relationship between FGF23 and anemia in HD and renal transplant patients

Baloğlu, İsmail; Ozer, Hakan; Öztürk, Yasin; Erdur, Mehmet Fatih; Tonbul, Halil Zeki; Türkmen, Kültiğin

doi:10.1007/s11255-021-02982-9

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FGF-23 levels are high in RTx-p during the first 6 months after RTx and are significant in the development and maintenance of low P levels. At the moment, some recent evidence has reported a relationship in RTx-p of FGF-23 levels of RTx with anaemia status and cardiovascular risk ( 21 , 22 ).…”

Section: Mineral and Bone Disorder In Rtxmentioning

confidence: 99%

Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects

et al. 2022

View full text Add to dashboard Cite

Renal transplantation (RTx) allows us to obtain the resolution of the uremic status but is not frequently able to solve all the metabolic complications present during end-stage renal disease. Mineral and bone disorders (MBDs) are frequent since the early stages of chronic kidney disease (CKD) and strongly influence the morbidity and mortality of patients with CKD. Some mineral metabolism (MM) alterations can persist in patients with RTx (RTx-p), as well as in the presence of complete renal function recovery. In those patients, anomalies of calcium, phosphorus, parathormone, fibroblast growth factor 23, and vitamin D such as bone and vessels are frequent and related to both pre-RTx and post-RTx specific factors. Many treatments are present for the management of post-RTx MBD. Despite that, the guidelines that can give clear directives in MBD treatment of RTx-p are still missed. For the future, to obtain an ever-greater individualisation of therapy, an increase of the evidence, the specificity of international guidelines, and more uniform management of these anomalies worldwide should be expected. In this review, the major factors related to post-renal transplant MBD (post-RTx-MBD), the main mineral metabolism biochemical anomalies, and the principal treatment for post-RTx MBD will be reported.

show abstract

Section: Mineral and Bone Disorder In Rtxmentioning

confidence: 99%

Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Decreases in FGF-23 might contribute to the reduction of LVH and improvements of ventricular contractility after kidney transplantation (123,124). Baloglu et al reported that hemoglobin levels are inversely associated with circulating FGF-23, however this association was no longer significant after kidney transplantation (125).…”

Section: Post Kidney Transplant Patientsmentioning

confidence: 99%

The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation

et al. 2022

View full text Add to dashboard Cite

Cardiovascular disease and mineral bone disorders are major contributors to morbidity and mortality among patients with chronic kidney disease and often persist after renal transplantation. Ongoing hormonal imbalances after kidney transplant (KT) are associated with loss of graft function and poor outcomes. Fibroblast growth factor 23 (FGF-23) and its co-receptor, α-Klotho, are key factors in the underlying mechanisms that integrate accelerated atherosclerosis, vascular calcification, mineral disorders, and osteodystrophy. On the other hand, kidney donation is also associated with endocrine and metabolic adaptations that include transient increases in circulating FGF-23 and decreases in α-Klotho levels. However, the long-term impact of these alterations and their clinical relevance have not yet been determined. This manuscript aims to review and summarize current data on the role of FGF-23 and α-Klotho in the endocrine response to KT and living kidney donation, and importantly, underscore specific areas of research that may enhance diagnostics and therapeutics in the growing population of KT recipients and kidney donors.

show abstract

The relationship between FGF23 and anemia in HD and renal transplant patients

Cited by 2 publications

References 35 publications

Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects

Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects

The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation

Contact Info

Product

Resources

About